09 Jan ChromaDex Seeking to Redefine Its “Anti-Aging” Pill Persona
ChromaDex (NASDAQ: CDXC), a nutraceutical Company focussed on improving the way people age, announced the launch of a “first-of-its-kind” Phase 1 clinical study to test the safety, efficacy and potential of branded nicotinamide riboside (NR), Niagen, in improving the effects of exercise therapy in older adults with hypertension. The study is being sponsored by the University of Florida and is being conducted in collaboration with the National Institute of Ageing.
The Study, which was initiated as part of the ChromaDex External Research Program (CERP), involves ChromaDex supplying its NR and placebo, free of cost to research institution worldwide, and will be a randomized, double-blind study consisting of 74 hypertensive adults. Changes in arterial stiffness, blood pressure and walking performance are some of the parameters being evaluated as part of the study.
Robert Mankowski, PhD, Department of Aging and Geriatric Research, the University of Florida and the primary investigator commented,
“This clinical trial will provide valuable information on the potential of NR supplementation to enhance the benefits of exercise in older populations with hypertension. Published data suggest NR may support cardiovascular health with further study, specifically through improvements in blood pressure (BP) and aortic stiffness. However, older hypertensive adults have yet to be explored in a clinical study,”
The Company which is the world’s foremost scientific authority on nicotinamide adenine dinucleotide (NAD) and nicotinamide riboside (NR) science will be testing its patent-protected NR, a unique form of vitamin B3 that has demonstrated the ability to safely increase NAD+ levels in the body. NAD+ is a crucial coenzyme that promotes cellular energy production and mitochondrial function.
Exercise has proven to be beneficial in the management of Hypertension and improving cardiovascular health, however maintaining a regular exercise routine is challenging for the elderly, owing to age-associated physiological declines. Niagen has been successfully reviewed twice under the FDA’s new dietary ingredient (NDI) notification program, besides being notified to the FDA as generally recognized as safe (GRAS), making it the only commercially available nicotinamide riboside to enjoy this distinction, as per a Company statement.
Dr. Matthew Roberts ChromaDex Chief Scientific Officer opined,
“Through increases in NAD+, NR has the potential to improve cellular energy production, supplying individuals with the energy necessary to maintain a regular exercise routine. We look forward to enhancing our understanding of the use of NR as an adjuvant approach to exercise in promoting improvements in the cardiovascular health of aging adults.”
Market Cap: $265M; Current Share Price: 4.75 USD
Data by YCharts
Hypertension, commonly referred to as High Blood Pressure (HBP), is a chronic medical condition in which there is persistently elevated blood pressure in the arteries, leading to cardio-vascular and other complications. The condition can either develop gradually over a long period of time, namely Primary (Essential) Hypertension, or can develop due to an underlying medical condition namely Secondary Hypertension. Secondary hypertension develops suddenly and is usually characterised by higher blood pressure levels than primary hypertension. Some of the causes of secondary hypertension are renal problems, Obstructive Sleep Apnea, Adrenal Gland Tumors and Thyroid abnormalities.
Age, family history, obesity, level of physical activity, use of tobacco, alcohol, stress levels and chronic conditions such as diabetes are some of the contributing factors. Undetected and untreated hypertension can increase the risk of heart diseases and strokes, aneurysms, renal disorders, eye problems, metabolic syndromes, dementia to name a few. The treatment options for this condition begin with the prescription of lifestyle changes such as eating healthy food with low sodium content, regular exercise, reducing weight and restricting alcohol or tobacco usage.
The therapeutic options include use of diuretics that help eliminate sodium from the blood, Angiotensin-converting enzyme (ACE) inhibitors such as lisinopril (Zestril), benazepril (Lotensin), captopril (Capoten), Angiotensin II receptor blockers (ARBs) and calcium channel blockers, alpha blockers, beta blockers, Aldosterone antagonists, rennin inhibitors. The Global market of Anti-Hypertensive Drugs will reach $ USD 41.2 billion by 2023, growing at a CAGR of 2.73%, from $32.2 billion in 2015, according to a report by Market Research Future.
The CDC estimates that over 75 million American Adults, or 1 in 3 adults, suffer from high blood pressure. In addition Hypertension was a primary cause of death for more than 410,000 Americans in 2014. High Blood Pressure costs $48.6 billion each year including cost of health care services, medications to treat high blood pressure, and missed days of work.
ChromaDex is an integrated global nutraceutical Company that develops path-breaking products, establishes industry leading reference standards and offers expert consulting services. The Company licensed patents for the nutritional and therapeutic applications of its break-through ingredient nicotinamide riboside (NR) from Dartmouth College in 2014. Dr. Charles Brenner, who holds the patent for this ingredient, discovered the positive effects of nicotinamide riboside (NR) on oxidized nicotinamide adenine dinucleotide (NAD+) in humans. ChomaDex entered into an exclusive license with the Dartmouth College to commercialize these patents. The Company successfully commercialized NR and launched it under the brand name NIAGEN®. Niagen has undergone more than four clinical trials and demonstrated the ability to increase the levels of a vital cellular response that promotes healthy living and ageing, as per the Company.
Furthermore the Company is one of the leading providers of phytochemical reference standards, botanical reference materials, and research grade materials with more than 1800 phytochemicals and 400 botanical reference materials in their catalog. In addition, ChromaDex is engaged in the discovery, acquisition, development and commercialization of patented proprietary ingredient technologies such as IMMULINA™, a spirulina extract and AnthOrigin™, anthocyanins derived from a domestically-produced, water-extracted purple corn, besides NIAGEN.
The Company offers consulting services through two separate arms namely Spherix Consulting and in partnership with Joy’s Quality Management Systems (JQMS). ChromaDex also runs the ChromaDex External Research Program (CERP), formerly known as the Material Transfer Agreement program, as part of its Research and Development program. CERP provides ChromaDex material and technical expertise to exceptional preclinical and clinical research projects, free of cost. Till Date, the Company has developed over 185 MTA’s leading to the publishing of more than 40 publications.
ChromaDex has built a very strong intellectual property portfolio, with patents covering Niagen, Immulina, Pureenergy and pTeroPure, in the U.S as well as in the international markets.
Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.
Click here to please visit our detailed disclosure